A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer (NAPOLI 3).
APA
Wainberg ZA, Melisi D, et al. (2025). A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer (NAPOLI 3).. Future oncology (London, England), 21(7), 765-774. https://doi.org/10.1080/14796694.2025.2458458
MLA
Wainberg ZA, et al.. "A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer (NAPOLI 3).." Future oncology (London, England), vol. 21, no. 7, 2025, pp. 765-774.
PMID
39935331
같은 제1저자의 인용 많은 논문 (5)
- Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: a pilot phase 1 trial.
- Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial.
- Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results.
- NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3.
- Health-related quality of life with bemarituzumab plus mFOLFOX6 in patients with FGFR2b-overexpressing, advanced gastric or gastroesophageal junction cancer.